

Legal Notice and Disclaimer

Website & Electronic Communications - Innovata Pharmaceuticals (Pty) Ltd

INNOVATA PHARMACEUTICALS (PTY) LTD

Registration Number: 2013/093943/07 | Version 1.6 | Final -23 July 2026

1. Preamble and Scope

This Legal Notice and Disclaimer ("Notice") governs all electronic communications originating from or on behalf of Innovata Pharmaceuticals (Pty) Ltd (Registration Number: 2013/093943/07) ("Innovata", "the Company", "we", "us", "our"), including emails, email attachments, automated notifications, and any other electronic messages transmitted via the Company's systems.

This Notice also governs all content published on the Company website at <https://innovata.co.za> ("Website") and applies to any person who accesses, receives, reads, or acts upon any communication from the Company.

By receiving or accessing a communication from Innovata, or by using the Website, you confirm that you have read and understood this Notice and accept its terms.

2. Definitions

- "Communication" Any electronic mail message, attachment, automated notification, or electronic message sent from or on behalf of Innovata, including all content in a thread originating from the Company.
- "Company Systems" All hardware, software, servers, networks, cloud platforms, and infrastructure used by Innovata to transmit, receive, store, or process Communications.
- "Information" All data, text, images, documents, trade secrets, proprietary information, and intellectual property contained in or attached to a Communication.
- "Personal Information" Any information relating to an identified or identifiable natural or juristic person, as defined in the Protection of Personal Information Act 4 of 2013 ("POPIA").
- "Recipient" Any person, entity, or system that receives, accesses, or reviews a Communication from the Company, whether the intended recipient or not.
- "Website" The Company website accessible at <https://innovata.co.za> and all pages, subdomains, and content published thereon.

3. Identification of Sending Entity

All Communications are sent by or on behalf of Innovata Pharmaceuticals (Pty) Ltd, a private company incorporated and registered under the laws of the Republic of South Africa (Registration Number: 2013/093943/07), with its principal place of business at 100 Northern Parkway Road, Crownwood Office Park, Block D, Ground Floor, Ormonde, City of Johannesburg, Gauteng, 2001, South Africa.

The full name and registration number of the sending entity appear in the signature block of the originating Communication or are available on request. For data protection enquiries, contact the Information Officer at popia@innovata.co.za.

No Communication from Innovata creates any agency, partnership, joint venture, or other legal association between the Company and any third party unless reduced to a formal written agreement signed by an authorised representative of the Company.

Innovata Pharmaceuticals (Pty) Ltd

Crownwood Office Park, 100 Northern Parkway, Ormonde, 2091 Johannesburg, South Africa

Tel: +27 (0) 86 999 0912 | fax2email: +27 (0) 86 585 5115 | email: grace@innovata.co.za

www.innovata.co.za

4. Confidentiality

All Information transmitted in a Communication is strictly confidential and may be subject to legal professional privilege, litigation privilege, or commercial confidentiality. It is intended solely for the use of the named addressee.

If you have received this Communication in error, you are required to:

- Notify the sender immediately by reply email.
- Permanently delete the Communication and all copies from your systems.
- Refrain from reading, copying, disclosing, distributing, or acting on the Communication in any way.
- Not retain any copy of the Communication or its contents.

Any use, disclosure, or copying of a misdirected Communication is strictly prohibited and may be unlawful under South African law, including POPIA and the Electronic Communications and Transactions Act 25 of 2002 ("ECTA").

5. Email and Website Disclaimer and Limitations

5.1 No warranty as to accuracy

Communications and the Information contained therein are provided in good faith but without warranty as to accuracy, completeness, timeliness, or fitness for any particular purpose. Opinions expressed in a Communication are those of the individual author and do not necessarily represent the position of Innovata.

5.2 No contract formation by email

A Communication, in itself, does not constitute, vary, amend, or conclude a legally binding contract. No employee, agent, or representative of Innovata has authority to conclude any binding commitment on behalf of the Company by electronic communication alone without express written confirmation executed by an authorised signatory of the Company under a formal written agreement.

5.3 Virus and malware

Recipients are responsible for conducting their own virus and malware checks on all Communications and attachments. Innovata accepts no liability for any damage, loss, or disruption arising from malicious code, corrupted files, or other harmful material transmitted via a Communication, notwithstanding reasonable precautions taken by the Company.

5.4 Monitoring of communications

All Communications sent to or from Company Systems are subject to monitoring, recording, filtering, and archiving for the purposes of security, compliance with legal and regulatory obligations, pharmacovigilance record-keeping, prevention of data loss, and internal policy enforcement. By communicating with Innovata electronically, you acknowledge and consent to such monitoring to the extent permitted by applicable law.

5.5 Delivery and technical failure

Innovata does not guarantee the secure, complete, or timely delivery of Communications. The Company accepts no liability for loss, interception, corruption, or delay caused by technical failure, network interruptions, spam filtering systems, or any other cause outside the Company's reasonable control. If you are reporting a suspected adverse event or product safety concern and do not receive acknowledgement promptly, please contact us by telephone using the details in Section 13.

5.6 Banking details and payment instructions

Innovata's banking details do not change by email. Any communication appearing to change Innovata's banking, beneficiary, or electronic funds transfer details must be independently verified by telephone, using contact

Innovata Pharmaceuticals (Pty) Ltd

Crownwood Office Park, 100 Northern Parkway, Ormonde, 2091 Johannesburg, South Africa

Tel: +27 (0) 86 999 0912 | fax2email: +27 (0) 86 585 5115 | email: grace@innovata.co.za

www.innovata.co.za

details already held on record and not those supplied in the communication, before any payment is made or any change is effected. Innovata accepts no liability for any loss arising from a failure to verify banking details in this manner. Where Innovata issues a bank confirmation letter electronically, it will be password-protected and the password provided separately by telephone or other voice channel.

5.7 No admission of liability

Nothing in any Communication constitutes an admission of liability, guilt, fault, or wrongdoing of any kind by Innovata, its directors, employees, or agents.

5.8 Vicarious liability

Innovata is not liable for the personal views, opinions, or statements expressed by any sender where those views are not directly related to the official business of the Company, or where the sender has acted outside the scope of their employment or authority.

6. Limitation of Liability

To the fullest extent permitted by applicable South African law, including the Consumer Protection Act 68 of 2008 ("CPA") and ECTA, Innovata, its directors, officers, employees, and agents shall not be liable for any loss or damage of any nature arising from the use of, reliance on, or inability to use any Communication or Information contained therein; any inaccuracy, omission, or error in any Communication; any interception, loss, alteration, or corruption of a Communication in transit; any virus or harmful code transmitted via a Communication; or any action taken in reliance on a Communication that does not constitute a formally executed written agreement. Nothing in this clause excludes liability that cannot lawfully be excluded under applicable law, including liability for personal injury arising from a defective product, which is addressed through Innovata's product safety and pharmacovigilance procedures rather than through this Notice.

7. Intellectual Property

All intellectual property rights in Communications, the Website, and their contents, including copyright, trademarks, product names, and any proprietary methodologies or documentation, vest in and remain the sole property of Innovata or its licensors. No Communication or use of the Website grants any licence, right, or interest in any intellectual property of Innovata, except as expressly set out in a formal written agreement.

8. Data Protection and Privacy

Any Personal Information contained in or transmitted via a Communication is processed by Innovata in accordance with POPIA and the Company's Privacy and Data Protection Policy (Annexure C). Data subjects wishing to exercise their rights under POPIA must contact the Information Officer at popia@innovata.co.za.

9. Evidence and Record Preservation

Communications may constitute business records and may be subject to legal hold obligations in the event of pending or reasonably anticipated litigation, regulatory investigation, or dispute. Innovata retains email correspondence for an extended period as set out in its IT Master Policy to support regulatory record-keeping, litigation readiness, and audit trail integrity in the pharmaceutical sector. Destruction of a Communication subject to a legal hold may constitute spoliation of evidence and attract legal sanctions.

10. Medical and Product Information Disclaimer

Nothing published on the Website, or contained in any Communication, constitutes medical advice, a recommendation for treatment, or a substitute for consultation with a qualified healthcare professional. Product

Innovata Pharmaceuticals (Pty) Ltd

Crownwood Office Park, 100 Northern Parkway, Ormonde, 2091 Johannesburg, South Africa

Tel: +27 (0) 86 999 0912 | fax2email: +27 (0) 86 585 5115 | email: grace@innovata.co.za

www.innovata.co.za

information published on the Website is intended primarily for healthcare professionals in South Africa and is provided in accordance with the professional information approved by the South African Health Products Regulatory Authority (“SAHPRA”) for the relevant product. Patients and members of the public should always consult their doctor or pharmacist before starting, stopping, or changing any medicine.

If you wish to report a suspected adverse event, side effect, or product quality complaint relating to an Innovata product, please contact us at safety@innovata.co.za or refer to the reporting details published on the Website. Adverse events may also be reported directly to SAHPRA.

11. Governing Law and Jurisdiction

This Notice and all Communications are governed by and construed in accordance with the laws of the Republic of South Africa. Any dispute arising from or in connection with a Communication, or from the application of this Notice, shall be subject to the exclusive jurisdiction of the courts of South Africa having competent jurisdiction.

12. Severability

If any provision of this Notice is found to be invalid, unlawful, or unenforceable by a court of competent jurisdiction, that provision shall be severed from the remainder of the Notice, which shall continue in full force and effect. The failure of Innovata to enforce any provision of this Notice does not constitute a waiver of that or any other provision.

13. Contact Details

Company	Innovata Pharmaceuticals (Pty) Ltd
Registration number	2013/093943/07
Address	100 Northern Parkway Road, Crownwood Office Park, Block D, Ground Floor, Ormonde, City of Johannesburg, Gauteng, 2001, South Africa
Telephone	+27 86 999 0912
Website	https://innovata.co.za
General enquiries	info@innovata.co.za
Data protection / POPIA	popia@innovata.co.za
Medical information	medinfo@innovata.co.za
Adverse event / product safety reporting	safety@innovata.co.za

Innovata Pharmaceuticals (Pty) Ltd

Crownwood Office Park, 100 Northern Parkway, Ormonde, 2091 Johannesburg, South Africa

Tel: +27 (0) 86 999 0912 | fax2email: +27 (0) 86 585 5115 | email: grace@innovata.co.za

www.innovata.co.za